Bristol-Myers Squibb employees ride across the U.S. to raise money to support cancer research by Stand Up To Cancer

Bristol-Myers SquibbThe first of seven teams of Bristol-Myers Squibb (NYSE:BMY) employees mounted their bikes in Cannon Beach, OR, today to kick off the 2017 Coast 2 Coast 4 Cancer Ride. Ninety-three novice riders will bike a total of nearly 2,800 miles during the 21-day mission to raise money and awareness for Stand Up To Cancer’s innovative cancer research programs that bring together collaborative teams of scientific researchers to help get new therapies to patients faster.

Bristol-Myers Squibb will match funds raised during the 2017 Coast 2 Coast 4 Cancer Ride dollar-for-dollar up to a total of $500,000. This is the fourth Coast 2 Coast 4 Cancer Ride benefitting Stand Up To Cancer (SU2C). Last year’s Coast 2 Coast 4 Cancer ride raised over $1 million for SU2C research programs.

Katie Couric, award-winning journalist and SU2C co-founder said, "All of us at Stand Up To Cancer are profoundly grateful to the Bristol-Myers Squibb employees as they cycle cross-country. Their commitment honors those who are fighting cancer, as well as those lost to the disease. The riders - and everyone who supports them - are helping SU2C advance research with the hope of one day turning more and more cancer patients into long-term survivors."

This year, Bonni Norwood of Spring Lakes, MI, a cancer survivor herself who hasn’t ridden a bike in 45 years, will ride from Kansas City, MO, to Indianapolis, IN. "While training to ride 75 miles per day is difficult for me, my struggles pale in comparison to those faced by people fighting cancer," said Bonni. "I'm riding for two dear friends who are both young and vibrant, but are currently battling cancer. When I face steep climbs or cross winds, I will dig deep and persevere for them and for all cancer patients."

"Every day, we, at Bristol-Myers Squibb, challenge ourselves individually and collectively as a team to fight cancer," said Teresa Bitetti, senior vice president, U.S. Oncology, Bristol-Myers Squibb. "Our employees who are riding across the country exemplify this passion and purpose - to help drive real change for people impacted by cancer."

Concurrently, seventy-eight Bristol-Myers Squibb employees in Europe will embark on a Country 2 Country 4 Cancer Ride . The Country 2 Country Ride kicks off September 8 in Germany, and spans 3,600 kilometers (2,236 miles) through Switzerland, Italy, France, Spain, and the United Kingdom. Funds raised will support one of eight market-specific cancer-focused charities in Europe.

About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

About Stand Up To Cancer
Stand Up To Cancer (SU2C) raises funds to accelerate the pace of research to get new therapies to patients quickly and save lives now. SU2C, a division of the Entertainment Industry Foundation (EIF), a 501(c)(3) charitable organization, was established in 2008 by film and media leaders who utilize the industry’s resources to engage the public in supporting a new, collaborative model of cancer research, and to increase awareness about cancer prevention as well as progress being made in the fight against the disease. As SU2C's scientific partner, the American Association for Cancer Research (AACR) and a Scientific Advisory Committee led by Nobel Laureate Phillip A. Sharp, PhD, conduct rigorous, competitive review processes to identify the best research proposals to recommend for funding, oversee grants administration, and provide expert review of research progress.

Current members of the SU2C Council of Founders and Advisors (CFA) include Katie Couric, Sherry Lansing, Lisa Paulsen, Rusty Robertson, Sue Schwartz, Pamela Oas Williams, Ellen Ziffren, and Kathleen Lobb. The late Laura Ziskin and the late Noreen Fraser are also co-founders. Sung Poblete, PhD, RN, has served as SU2C’s president and CEO since 2011.

Most Popular Now

Scientists uncover SARS-CoV-2-specific T cell immu…

The study by scientists from Duke-NUS Medical School, in close collaboration with the National University of Singapore (NUS) Yong Loo Lin School of Medicine, Singapore Ge...

Common FDA-approved drug may effectively neutraliz…

A common drug, already approved by the Food and Drug Administration (FDA), may also be a powerful tool in fighting COVID-19, according to research published this week in ...

Drug linked to 45% lower risk of dying among COVID…

Critically ill COVID-19 patients who received a single dose of a drug that calms an overreacting immune system were 45% less likely to die overall, and more likely to be ...

Neutralizing antibodies isolated from COVID-19 pat…

Researchers at Columbia University Irving Medical Center have isolated antibodies from several COVID-19 patients that, to date, are among the most potent in neutralizing ...

GSK and CureVac announce strategic mRNA technology…

GlaxoSmithKline plc (LSE/NYSE: GSK) and CureVac announced the signing of a strategic collaboration agreement for the research, development, manufacturing and commercialis...

Pfizer and BioNTech granted FDA Fast Track designa…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX, "BioNTech") announced that two of the companies' four investigational vaccine candidates from their BNT162 mRNA-bas...

Sanofi and Regeneron provide update on Kevzara® (s…

Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that the U.S. Phase 3 trial of Kevzara® (sarilumab) 400 mg in COVID-19 patients requiring mechanical v...

Novartis launches first-of-its-kind not-for-profit…

Novartis announced a new initiative to help patients in low-income and lower-middle-income countries (LIC; LMIC) access affordable medicines to treat the major symptoms o...

COVID-19 vaccine AZD1222 showed robust immune resp…

Interim results from the ongoing Phase I/II COV001 trial, led by Oxford University, showed AZD1222 was tolerated and generated robust immune responses against the SARS-Co...

Another mRNA-based vaccine candidate protects anim…

An experimental messenger RNA (mRNA)-based vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) elicits protective immune responses in mice and no...

Pfizer and BioNTech announce an agreement with U.S…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced the execution of an agreement with the U.S. Department of Health and Human Services and the Department of...

Pfizer and BioNTech announce agreement with the Un…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced an agreement with the United Kingdom to supply 30 million doses of their BNT162 mRNA-based vaccine candid...